Author: Schäfer, Alexandra; Muecksch, Frauke; Lorenzi, Julio C. C.; Leist, Sarah R.; Cipolla, Melissa; Bournazos, Stylianos; Schmidt, Fabian; Gazumyan, Anna; Baric, Ralph S.; Robbiani, Davide F.; Hatziioannou, Theodora; Ravetch, Jeffrey V.; Bieniasz, Paul D.; Nussenzweig, Michel C.; Sheahan, Timothy P.
Title: Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo Cord-id: 4tu1t6wa Document date: 2020_9_15
ID: 4tu1t6wa
Snippet: SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination
Document: SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination in vivo. Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA. The data indicate that hu-mAb protective activity is dependent on intact effector function and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.
Search related documents:
Co phrase search for related documents- accession number and lung tissue: 1
- accreditation assessment and lung tissue: 1
- action mechanism and adaptive immune response: 1, 2, 3
- action mechanism and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and adaptive immunity innate: 1, 2, 3, 4, 5
- action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- action mechanism and lung titer: 1
- action mechanism and macrophage polarization: 1, 2
- activating receptor and adaptive immunity: 1, 2, 3
- activating receptor and adaptive immunity innate: 1, 2
- activating receptor and lung tissue: 1, 2
- activating receptor and macrophage polarization: 1
- adaptive immune response and ade dependent enhancement: 1
- adaptive immune response and lung tissue: 1, 2, 3, 4, 5, 6, 7
- adaptive immune response and macrophage polarization: 1, 2
Co phrase search for related documents, hyperlinks ordered by date